Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for TECX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 223.85M
March 31, 2026 230.42M
December 31, 2025 251.33M
September 30, 2025 267.53M
June 30, 2025 283.77M
March 31, 2025 301.04M
December 31, 2024 140.78M
September 30, 2024 150.36M
June 30, 2024 166.37M
March 31, 2024 88.84M
December 31, 2023 -84.64M
September 30, 2023 102.86M
June 30, 2023 122.04M
March 31, 2023 53.00M
December 31, 2022 75.37M
September 30, 2022 98.09M
June 30, 2022 118.34M
March 31, 2022 143.16M
Date Value
December 31, 2021 169.48M
September 30, 2021 193.57M
June 30, 2021 220.99M
March 31, 2021 232.93M
December 31, 2020 254.34M
September 30, 2020 207.87M
June 30, 2020 239.79M
March 31, 2020 256.52M
December 31, 2019 186.01M
September 30, 2019 206.76M
June 30, 2019 92.63M
March 31, 2019 106.79M
December 31, 2018 122.18M
September 30, 2018 137.11M
June 30, 2018 148.32M
March 31, 2018 53.99M
December 31, 2017 3.365M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics